Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221

Next Previous
X
Search
Trial Profile

An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 20 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Expanded access
  • Acronyms DCVax-L EAP
  • Sponsors Northwest Biotherapeutics

    • Most Recent Events

    • 04 Jun 2019 Follow-up survival data, presented in a Northwest Biotherapeutics media release.
    • 27 Mar 2015 Survival data in 51 patients published in Northwest Biotherapeutics media release.
    • 27 Mar 2015 Survival data in 51 patients presented at 2nd Immunotherapy of Cancer (ITOC) Conference in Germany, according to a Northwest Biotherapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top